RESTON, Va., Nov. 6, 2017 /PRNewswire/ -- Leidos (NYSE: LDOS), a FORTUNE 500® science and technology company, was awarded a prime contract by the Naval Health Research Center (NHRC) to continue to provide research and development support services to the Warfighter Performance department. The single-award cost-plus-fixed fee follow-on contract has a ten-month base period of performance, four one-year options, and a total contract ceiling of approximately $29 million if all options are exercised. Work will be performed primarily in San Diego, Calif.
The NHRC Warfighter Performance department conducts research related to the measurement, maintenance, restoration, enhancement, and modeling of human performance in military operational environments. Under the contract, Leidos will leverage its expertise in science and technology to support the NHRC in maximizing the operational performance and enhance warfighter resilience, both physiological and psychological, as well as improve assessment, diagnosis, and advanced rehabilitation strategies to optimize warfighter reset to optimize mission readiness. Specifically, the Leidos Naval Health team will conduct medical research, development, testing, evaluation, and surveillance to enhance deployment readiness of Department of Defense personnel worldwide.
"We are pleased to continue supporting the Naval Health Research Center and providing the scientific and technical expertise to help ensure our military personnel are ready for duty, and can perform at the highest levels - both physically and psychologically," said Leidos Group President Jon Scholl.
Leidos is a Fortune 500® science and technology solutions and services leader working to solve the world's toughest challenges in the defense, intelligence, homeland security, civil, and health markets. The company's 32,000 employees support vital missions for government and commercial customers. Headquartered in Reston, Virginia, Leidos reported annual revenues of approximately $7.04 billion for the fiscal year ended December 30, 2016. For more information, visit www.Leidos.com.
Statements in this announcement, other than historical data and information, constitute forward-looking statements that involve risks and uncertainties. A number of factors could cause our actual results, performance, achievements, or industry results to be very different from the results, performance, or achievements expressed or implied by such forward-looking statements. Some of these factors include, but are not limited to, the risk factors set forth in the company's Annual Report on Form 10-K for the period ended December 30, 2016, and other such filings that Leidos makes with the SEC from time to time. Due to such uncertainties and risks, readers are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof.